Patents by Inventor Charles R. Spillert
Charles R. Spillert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8530455Abstract: Glucono-delta-lactone (GDL) can be used to mediate the human blood coagulation process. In particular, GDL can be used in an assay to determine an individual's risk potential for accelerated blood clotting or as a treatment for conditions related to accelerated clotting potential and/or inflammatory states.Type: GrantFiled: August 5, 2010Date of Patent: September 10, 2013Assignee: University of Medicine and Dentistry of New JerseyInventors: Charles R. Spillert, Debbie Persaud
-
Publication number: 20110071219Abstract: Glucono-delta-lactone (GDL) can be used to mediate the human blood coagulation process. In particular, GDL can be used in an assay to determine an individual's risk potential for accelerated blood clotting or as a treatment for conditions related to accelerated clotting potential and/or inflammatory states.Type: ApplicationFiled: August 5, 2010Publication date: March 24, 2011Applicant: University of Medicine and Dentistry of New JerseyInventors: Charles R. Spillert, Debbie Persaud
-
Patent number: 7094428Abstract: A hemostatic composition which comprises at least one procoagulant metal ion, such as silver (I) or mercury (II), and at least one procoagulant biopolymer, such as collagen, thrombin, prothrombin, fibrin, fibrinogen, heparinase, Factor VIIa, Factor VIII, Factor IXa, Factor Xa, Factor XII, von Willebrand Factor, a selectin, a procoagulant venom, a plasminogen activator inhibitor, glycoprotein IIb-IIIa, a protease, or plasma. The composition in the form of a paste, dough, glue, liquid, lyophilized powder or foam, may be provided, for application to a wound. A hemostatic device is also described which comprises a hemostatic composition as described above. The device may be in the form of, for example, a plug, bandage, gauze, cloth, tampon, membrane or sponge. Methods are also provided for prophylaxis or treatment of bleeding at a site by application to the site of the composition or device as described.Type: GrantFiled: December 10, 2002Date of Patent: August 22, 2006Assignee: The University of Medicine and Dentistry of New JerseyInventors: Charles R. Spillert, Marcelle Khalil
-
Publication number: 20030129183Abstract: A hemostatic composition which comprises at least one procoagulant metal ion, such as silver (I) or mercury (II), and at least one procoagulant biopolymer, such as collagen, thrombin, prothrombin, fibrin, fibrinogen, heparinase, Factor VIIa, Factor VIII, Factor IXa, Factor Xa, Factor XII, von Willebrand Factor, a selectin, a procoagulant venom, a plasminogen activator inhibitor, glycoprotein IIb-IIIa, a protease, or plasma. The composition in the form of a paste, dough, glue, liquid, lyophilized powder or foam, may be provided, for application to a wound. A hemostatic device is also described which comprises a hemostatic composition as described above. The device may be in the form of, for example, a plug, bandage, gauze, cloth, tampon, membrane or sponge. Methods are also provided for prophylaxis or treatment of bleeding at a site by application to the site of the composition or device as described.Type: ApplicationFiled: December 10, 2002Publication date: July 10, 2003Inventors: Charles R. Spillert, Marcelle Khalil
-
Patent number: 6514766Abstract: Methods for enhancing the value of the traditional erythrocyte sedimentation rate (ESR) test are provided by including an ESR-modifying agent, such as a metal ion, in the sample. Results of the resulting modified ESR are correlated with the health status of the animal.Type: GrantFiled: July 25, 2001Date of Patent: February 4, 2003Inventors: Charles R. Spillert, Marcelle Khalil
-
Publication number: 20020115222Abstract: Methods for enhancing the value of the traditional erythrocyte sedimentation rate (ESR) test are provided by including an ESR-modifying agent, such as a metal ion, in the sample. Results of the resulting modified ESR are correlated with the health status of the animal.Type: ApplicationFiled: July 25, 2001Publication date: August 22, 2002Inventors: Charles R. Spillert, Marcelle Khalil
-
Patent number: 6245573Abstract: This invention relates to diagnostic methods and test kits for rapidly assessing the coagulant activity of blood by measuring the rate of blood clotting in the presence of certain metal ions. A modulator of coagulation may also be included. The coagulation activity of the blood of the patient in the presence of metal ions and an optional modulator is an indication of the presence or development of certain pathological conditions relating to the procoagulant activity of blood, including platelet function. The effect of metal ions on the viscosity of blood is also diagnostically useful.Type: GrantFiled: February 12, 1998Date of Patent: June 12, 2001Assignee: University of Medicine and Dentistry of New JerseyInventor: Charles R. Spillert
-
Patent number: 5792660Abstract: This invention involves a method of analyzing a body fluid such as blood from a patient to determine whether or not there is a significant difference or change in the comparative determinants of viscosity in the body fluid sample, the comparative determinants being derived using a probe which provides increased sensitivity and corresponding improved relative viscosity values when used together with a suitable viscosity device, in order to identify the presence or incipiency of a symptomatic or asymptomatic pathology caused by or leading to said differences or changes in viscosity.Type: GrantFiled: October 2, 1996Date of Patent: August 11, 1998Assignee: University of Medicine and Dentistry of New JerseyInventors: Charles R. Spillert, Eric J. Lazaro
-
Patent number: 5783447Abstract: A method of analyzing samples of whole blood from a patient is disclosed which involves determining whether or not there is a significant difference or change in the comparative determinants of hypercoagulability in the sample. The comparative determinants are derived using two or more different detection systems, or two or more components of a single detection system, especially two or more probes, which provide variable force-induced energy inputs to the samples being measured in order to identify the presence of incipiency of a symptomatic or asymptomatic pathology caused by, or leading to, differences or changes in hypercoagulability.Type: GrantFiled: October 2, 1996Date of Patent: July 21, 1998Assignee: University of Medicine and Dentistry of New JerseyInventors: Charles R. Spillert, Eric J. Lazaro
-
Patent number: 4900679Abstract: There is disclosed a method of testing, and a kit therefor, a cellular hematologic fluid derived from a mammal to determine the existence in the mammal of a pathological state or condition wherein an immunomodulator is admixed with the cellular hematologic fluid of the mammal and a reaction parameter determined and compared with known reaction parameters of cellular hematologic fluids of mammals of known healthy states to like immunomodulator. In a preferred embodiment of the present invention, the reaction parameter is a clotting parameter as determined as fibrin levels.Type: GrantFiled: August 23, 1988Date of Patent: February 13, 1990Assignee: University of Medicine and Dentistry of New JerseyInventors: Charles R. Spillert, William A. Suval, Eric J. Lazaro
-
Patent number: 4833132Abstract: There is disclosed a process for treating a warm-blooded animal wherein there is administered to the warm-blooded animal a therapeutically effective amount of composition selected from the group consisting of 5-methyl-3-sulfanilamidoisoxazole, a salt of 5-methyl-3-sulfanilamidoisoxazole with a pharmaceutically acceptable base, 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine, a salt of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine with a pharmaceutically acceptable acid and mixtures thereof. The composition is useful to treat a fibrosarcoma (SAD.sub.2) tumor in warm-blooded animals.Type: GrantFiled: March 23, 1987Date of Patent: May 23, 1989Assignee: University of Medicine and Dentistry of New JerseyInventors: Charles R. Spillert, Corinne Devereux, Eric J. Lazaro
-
Patent number: 4814247Abstract: There is disclosed a method of testing a cellular hematologic fluid derived from a mammal to determine the existence in the mammal of a pathological state or condition wherein an immunomodulator is admixed with the cellular hematologic fluid of the mammal and a reaction parameter determined and compared with known reaction parameters of cellular hematologic fluids of mammals of known healthy states to like immunomodulator. In a preferred embodiment of the present invention, the reaction parameter is a clotting parameter as determined as fibrin levels.Type: GrantFiled: March 16, 1987Date of Patent: March 21, 1989Assignee: University of Medicine and Dentistry of New JerseyInventors: Charles R. Spillert, William A. Suval, Eric J. Lazaro
-
Patent number: 4705756Abstract: A method of testing a cellular hematologic fluid derived from a mammal to determine the existence in the mammal of a pathological state or condition wherein an immunomodulator is admixed with the cellular hematologic fluid of the mammal and a reaction parameter determined and compared with known reaction parameters of cellular hematologic fluids of mammals of known healthy states to like immunomodulator. In a preferred embodiment of the present invention, the reaction parameter is a clotting parameter as determined as fibrin levels.Type: GrantFiled: May 16, 1985Date of Patent: November 10, 1987Assignee: University of Medicine and Dentistry of New JerseyInventors: Charles R. Spillert, William D. Suval, Eric J. Lazaro
-
Patent number: 4698335Abstract: There is disclosed a process for treating a warm-blooded animal to be subjected to radiotherapy or chemotherapy wherein there is administered to the warm-blooded animal a therapeutically effective amount of a composition selected from the group consisting of 5-methyl-3-sulfanilamidoisoxazole, a salt of 5-methyl-3-sulfanilamidoisoxazole with a pharmaceutically acceptable base, 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine, a salt of 2,4-diamino-5-(3,4,5-trimethoxybenzene) pyrimidine with a pharmaceutically acceptable acid and mixtures thereof.Type: GrantFiled: September 27, 1984Date of Patent: October 6, 1987Assignee: University of Medicine & Dentistry of New JerseyInventors: Charles R. Spillert, Corinne Devereux, Eric J. Lazaro
-
Patent number: 4661478Abstract: There is disclosed a process for treating a warm-blooded animal subjected to barbituate anesthesia to potentiate effects thereof wherein there is administered to the warm-blooded animal a therapeutically effective amount of a composition selected from the group consisting of 5-methyl-3-sulfanilamidoisoxazole, a salt of 5-methyl-3-sulfanilamidoisoxazole with a pharmaceutically acceptable base, 2,4-diamino-5-3-(3,4,5-trimethoxybenzyl) pyrimidine, a salt of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine with a pharmaceutically acceptable acid and mixtures thereof.Type: GrantFiled: September 27, 1984Date of Patent: April 28, 1987Assignee: University of Medicine and Dentistry of New JerseyInventors: Charles R. Spillert, Corinne Devereux, Eric J. Lazaro
-
Patent number: 4632919Abstract: There is disclosed a process for prolonging recalcification, prothrombin and thrombin times of human plasma which comprises administering to a warm-blooded animal a composition selected from the group consisting of 5-methyl-3-sulfanilamidoisoxazole, a salt of 5-methyl-3-sulfanilamidoisoxazole with a pharmaceutically acceptable base, 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine, a salt of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine with a pharmaceutically acceptable acid and mixtures thereof.Type: GrantFiled: September 27, 1984Date of Patent: December 30, 1986Assignee: University of Medicine & Dentistry of N.J.Inventors: Charles R. Spillert, Corinne Devereux, Eric J. Lazaro
-
Patent number: 4632920Abstract: There is disclosed a process for treating a warm-blooded animal following burn injury wherein there is administered to the warm-blooded animal a therapeutically effect amount of a composition selected from the group consisting of 5-methyl-3-sulfanilamidoisoxazole, a salt of 5-methyl-3-sulfanilamidoisoxazole with a pharmaceutically acceptable base, 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine, a salt of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrmidine with a pharmaceutically acceptable acid and mixtures thereof.Type: GrantFiled: September 27, 1984Date of Patent: December 30, 1986Assignee: University of Medicine & Dentistry of New JerseyInventors: Charles R. Spillert, Corinne Devereux, Eric J. Lazaro